Opus Genetics Names Rob Gagnon, CPA, MBA, As Chief Financial Officer To Lead Financial Strategy and Growth In Gene Therapy And Ophthalmic Drug Development

Opus Genetics, Inc., a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, has announced the appointment of Rob Gagnon, CPA, MBA, as its Chief Financial Officer. Gagnon is a seasoned biotech executive with more than 20 years of financial and operational leadership experience across both public and private companies. Over the course of his career, he has raised more than $2 billion in capital, guided companies through IPOs, late-stage clinical development, commercial launches, and mergers and acquisitions, and played a key role in executing multiple strategic transactions.

Before joining Opus, Gagnon was the Chief Financial Officer at Remix Therapeutics, where he led the finance function, managed the strategic financing process, supported fundraising initiatives, and prepared the company for its IPO. Prior to that, he served as Chief Financial Officer and Chief Business Officer at Verastem Oncology, overseeing finance, business development, and investor relations while leading significant capital raising activities. He has also held senior finance leadership positions at Harvard Bioscience, Clean Harbors, and Biogen, following the early stages of his career in audit and advisory services with Deloitte and PricewaterhouseCoopers.

George Magrath, MD, Chief Executive Officer, Opus Genetics, stated, “Rob’s extensive experience in capital markets, strategic finance, and building high-performing organizations makes him an ideal fit for Opus as we continue advancing our clinical pipeline and prepare for multiple regulatory milestones. His track record of leading biotech companies through high-growth phases will be invaluable as we continue to execute on our vision of delivering transformative therapies for patients with significant unmet needs.”

Mr. Gagnon stated, “I’m excited to join Opus at such a pivotal stage, with late-stage clinical programs, a robust early pipeline, and strong momentum across gene therapy and small molecule platforms. I look forward to partnering with George and the Opus team to drive potential long-term growth as we work to deliver innovative inherited retinal disease therapies to patients worldwide.”

Gagnon holds an MBA from the MIT Sloan School of Management and a BA in Accounting from Bentley College. He is also a Certified Public Accountant in the Commonwealth of Massachusetts. In addition to his new role at Opus Genetics, he currently serves on the Board of Directors at Verastem Oncology, Harvard Bioscience, Purple Biotech, and Bone Biologics.